Virtus Biotech ETF BBP
Set alert
101.97 USD -2.21 -2.12%
At close · Nov 2
101.97 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
101.85 Day range 103.26
72.81 52-week range 110.05
- YTD
- +27.59%
- 1 year
- +36.63%
- Open
- 104.00
- Prev close
- 104.18
- Mkt cap
- 41.55M
- Vol
- 7.10K
- Avg vol
- 12.13K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 101.85
- High
- 103.26
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 63.72
- 200-d avg
- 60.18
2Y chart
Signals (104)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 26, 2026 | 4 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
Newest 20 of 104.
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 63.72
- 200-day average
- 60.18
About Virtus Biotech ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
News
Your note
Sign in to keep a note on BBP — it syncs with the Stock Master app.